In summary, although deal volume is down, there are fewer but larger deal sizes. Life sciences companies that can demonstrate ...

Meanwhile at SpinCo, a new spinoff of Galapagos, Henry Gosebruch was appointed CEO. Gosebruch was previously president and ...

As has been widely reported on, immunisation rates, including for flu and RSV, have been falling – at a troubling rate – and ...

Roche's Itovebi was the first PI3K inhibitor to get approved as a first-line treatment for breast cancer last year – and new ...

In particular, the organisation is unhappy with Kennedy's repeated assertions that Alzheimer's research has been dedicated to ...

Final draft guidance from NICE has backed NHS use of Filspari (sparsentan) for primary immunoglobulin A nephropathy (IgAN), ...

While not the first biologic to break into the COPD sector – Sanofi and Regeneron took that crown with the approval of their ...

This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie. In 1888, a 30-year-old ...

Novartis has another phase 3 trial win in its quiver for targeted factor B inhibitor iptacopan, building the case for the drug as a new oral therapy for diseases caused by disorders of the ...

Today, any pharma marketing strategy has to take into account the perspective of multiple stakeholders, such as doctors, regulators, payers and the patient. Here, we speak with Dr Simone Seiter ...

To remain relevant in an interconnected ecosystem, biopharma must go beyond optimising yesterday’s markets and begin ...

AstraZeneca has turned to another digital health partner to support its aspirations in chronic kidney disease (CKD), joining ...